We wrote about CRISPR Therapeutics (CRSP) on January 6 and said traders should "Continue to hold longs risking to $149 now. Our price targets are $200 and $230 for now." CRSP is now trading around $215 so I think another look at the stock is warranted and perhaps a change in strategy.
More from Investing
It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.
Short selling is a powerful tool, but it is not just the inverse of going long and requires a very different mindset to do it effectively.
I believe the markets are headed lower - probably not in a straight line or as steep as the last few days, but in a saw tooth fashion lower.
It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.